Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer (MRSI+RRP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01780701 |
Recruitment Status :
Completed
First Posted : January 31, 2013
Last Update Posted : April 27, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Prostate Cancer | Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe |
Study Type : | Observational |
Actual Enrollment : | 66 participants |
Observational Model: | Case-Crossover |
Time Perspective: | Prospective |
Official Title: | Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer |
Study Start Date : | January 2013 |
Actual Primary Completion Date : | January 2016 |
Actual Study Completion Date : | March 2017 |

Group/Cohort | Intervention/treatment |
---|---|
High risk prostate cancer patients
Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
|
Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe
Other Names:
|
Low risk prostate cancer patients
Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
|
Procedure: Magnetic Resonance Spectroscopy Imaging with rectal probe
Other Names:
|
- Number of participants with increased intraprostatic lipid concentration [ Time Frame: Up to 3 years ]Determine the correlation between the amount of intraprostatic lipid using 1H (proton) magnetic resonance spectroscopic imaging (MRSI) with an endorectal coil obtained prior to prostatectomy with fatty acid synthase protein expression measured in benign and cancer tissue from prostatectomy samples.
- Number of participants with increased tumor aggressiveness [ Time Frame: Up to 3 years ]Identify the association between fatty acid synthase protein expression in prostatectomy samples, intraprostatic lipid as measured by 1H MRSI, and prostate tumor aggressiveness.
- Number of participants with accumulation of lipid intermediates and proteins [ Time Frame: Up to 3 years ]To quantify the association between key metabolic intermediates involved in lipid metabolism, mitochondrial function, inflammation, and apoptosis in prostatectomy samples and fatty acid synthase protein expression, intraprostatic lipid and tumor aggressiveness.
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Prostate cancer diagnosis prior to treatment
- Age 21 years or older
- Signed informed subject consent
- Prostatectomy as planned prostate cancer treatment
Exclusion Criteria:
- Men who do not choose prostatectomy
- Men who have undergone any neoadjuvant therapy
- Men who have cardiac pacemakers or other implanted electronic devices
- Men who have any surgically implanted metal
- Men who have had any surgical procedure that precludes placement of endorectal probe
- Indication of dementia or memory issues listed on problem list
- Men who indicate exposure to ocular metal fragments; confirmed by positive ocular x-ray
- Men who are taking newly-prescribed (within 6 months of enrollment) lipid control medications

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01780701
United States, Oregon | |
Portland VA Medical Center | |
Portland, Oregon, United States, 97207 | |
Oregon Health & Science University Advanced Imaging Research Center | |
Portland, Oregon, United States, 97239 |
Principal Investigator: | Jackilen Shannon, PhD | Oregon Health and Science University | |
Principal Investigator: | Jonathan Q Purnell, MD | Oregon Health and Science University |
Responsible Party: | Jackie Shannon, Principal Investigator, OHSU Knight Cancer Institute |
ClinicalTrials.gov Identifier: | NCT01780701 |
Other Study ID Numbers: |
IRB00008458 W81XWH-12-1-0168 ( Other Grant/Funding Number: Dept of Defense ) 2978 ( Other Identifier: Portland VA Medical Center IRB ) 8458 ( Other Identifier: Oregon Health & Science University IRB ) Log #A-17208 ( Other Identifier: Dept of Defense Human Research Protection Office ) PC110361 ( Other Identifier: Dept of Defense ) |
First Posted: | January 31, 2013 Key Record Dates |
Last Update Posted: | April 27, 2017 |
Last Verified: | November 2016 |
prostate cancer aggressiveness magnetic resonance imaging fatty acid synthase |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |